Stamford, Conn., March 23, 2022 – Harm Reduction Therapeutics (HRT) will receive up to $11 million of additional financial support from Purdue Pharma L.P. to advance its development of a low-cost, over-the-counter (OTC) naloxone nasal spray in the United States....
Stamford, Conn., March 17, 2022 – Purdue Pharma L.P. is accepting proposals for investigator-initiated research (IIR) to assess opioid overdose reversal in Emergency Department (ED) and Emergency Medical Service (EMS) settings. Because we recognize there is value in...
When you access any of our websites, related other parties’ websites, mobile applications, or any electronic service, we may use cookies and other technologies to automatically collect information regarding you and your device to assess user activity and preferences. We may also use third-party analytic tools to assist with the collection of information including, but not limited to, Google Analytics. By using this site, you agree to our use of these technologies in accordance with our Privacy Policy.Ok
Privacy Policy Updates
Please read carefully the Purdue Pharma L.P. Privacy Policy (the “Privacy Policy”), which is part of the Purdue Pharma L.P. Terms and Conditions, before you access, download, or otherwise use any of our websites, related other parties’ websites, mobile applications, or any electronic service (collectively, the “Service”). This Privacy Policy describes the information collected through Your use of the Service, how we use it, how we share it, how we protect it, and the choices You can make about Your information.
